🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Boeing, crypto-exposed stocks, Savara surge premarket

Published 09/09/2024, 10:02 pm
© Reuters
US500
-
DJI
-
BA
-
DELL
-
MRK
-
ESZ24
-
1YMZ24
-
NQZ24
-
IXIC
-
SVRA
-
MARA
-
SMMT
-
BTC/USD
-
CLSK
-
PLTR
-
TERN
-
COIN
-

Investing.com -- US stock futures edged higher on Monday, pointing to a rebound on Wall Street after equities ended the prior session lower following an August jobs report that left traders uncertain about the size of potential Federal Reserve interest rate cuts.

By 06:31 ET (10:31 GMT), the Dow futures contract had gained 268 points or 0.7%, S&P 500 futures had increased by 42 points or 0.8%, and Nasdaq 100 futures had risen by 178 points or 1.0%.

Here are some of the biggest premarket US stock movers:

  • Shares in Boeing (NYSE:BA) jumped in premarket US trading on Monday after it tentatively agreed to a 25% pay increase for its biggest union, possibly averting a damaging strike that threatens to heap further pressure on the embattled planemaker.
  • Shares in crypto-related stocks like digital coin exchange Coinbase (NASDAQ:COIN) and crypto miners Cleanspark (NASDAQ:CLSK) and Marathon Digital (NASDAQ:MARA) advanced prior to the opening bell. Bitcoin, the world's most well-known digital token, gained on Monday, extending its drive higher into a third-consecutive day.
  • Palantir Technologies (NYSE:PLTR) and Dell (NYSE:DELL) both climbed on news that both of the firms will be joining the benchmark S&P 500.
  • Savara (NASDAQ:SVRA) surged following the release of data from a late-stage trial of the drug developer's investigative treatment for patients suffering from a rare lung disease.
  • Summit Therapeutics (NASDAQ:SMMT) spiked by more than 25% after the company unveiled fresh data showing that its lung cancer drug showed "statistically signficant improvement" in progression-free survival compared to Merck's Keytrude, Bloomberg News reported. Shares in Merck (NYSE:MRK) dropped.
  • Shares in Terns Pharmaceuticals (NASDAQ:TERN) rose sharply after it announced that its experimental oral obesity drug, TERN-601, helped patients in an early stage study lose weight by an average of 4.9%. The treatment also met the study's main goals of safety and tolerability, according to the group.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.